Editas Medicine Inc (NASDAQ:EDIT) shares, rose in value, with the stock price up by 0.79% to the previous day’s close as strong demand from buyers drove the stock to $1.28.
Actively observing the price movement in the last trading, the stock closed the session at $1.27, falling within a range of $1.25 and $1.3059. The value of beta (5-year monthly) was 2.164. Referring to stock’s 52-week performance, its high was $6.69, and the low was $0.91. On the whole, EDIT has fluctuated by -7.91% over the past month.
With the market capitalization of Editas Medicine Inc currently standing at about $107.15 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-04.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 786.1k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that EDIT’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of EDIT currently trading nearly 5.78% and -12.62% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 49.43, while the 7-day volatility ratio is showing 11.26% which for the 30-day chart, stands at 9.44%. Furthermore, Editas Medicine Inc (EDIT)’s beta value is 2.08, and its average true range (ATR) is 0.14.
A comparison of Editas Medicine Inc (EDIT) with its peers suggests the former has fared considerably weaker in the market. EDIT showed an intraday change of 0.79% in last session, and over the past year, it shrunk by -78.12%%.
Data on historical trading for Editas Medicine Inc (NASDAQ:EDIT) indicates that the trading volumes over the past 10 days have averaged 2.4 and over the past 3 months, they’ve averaged 3.77 million. According to company’s latest data on outstanding shares, there are 83.71 million shares outstanding.
Nearly 0.93% of Editas Medicine Inc’s shares belong to company insiders and institutional investors own 62.10% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 12.68 million shares as on 2025-03-31, resulting in a short ratio of 5.06. According to the data, the short interest in Editas Medicine Inc (EDIT) stood at 1934.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 13.77 million. The stock has risen by 0.79% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the EDIT stock heading into the next quarter.
